The Patent Finder

Lantern Pharma Inc.

5 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
May 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Method for treating rhabdoid tumors (US 11,844,772) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 1 fee due Oct 26, 2027
    The maintenance fee for Compositions and Methods of Use of Compounds to Increase Cancer Patient Survival Time (US 9,320,760) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,320,760Compositions and Methods of Use of Compounds to Increase Cancer Patient Survival Time
In force
 · Low confidence
In forceLow confidence
US 9,023,805Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
In force
 · High confidence
In forceHigh confidence
US 11,471,431Increasing cancer patient survival time by administration of dithio-containing compounds
In force
 · USPTO record
In forceUSPTO record
US 11,739,043Illudin Analogs, Uses Thereof, and Methods for Synthesizing the Same
In force
 · Medium confidence
In forceMedium confidence
US 11,844,772Method for treating rhabdoid tumors
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 5: 2 lapsed for an unpaid fee · 25 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

14 pending · 2 no status recorded

Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/023,098Method for Treating Breast Cancers and Parp Resistant Breast CancersJan 15, 2025Pending
18/973,932Treating Cancers with Combinations of Acylfulvenes with Ibrutinib And/Or BortezomibDec 9, 2024Pending
18/829,920Computerized Systems and Methods for Ensemble Model-Based Drug DiscoverySep 10, 2024Pending
18/669,238Method for Treating Cancer with Acylfulvene and RadiationMay 20, 2024Pending
18/425,632Treating Cancers with Combinations of Spironolactone and AcylfulvenesJan 29, 2024Pending
18/424,930Treating Cancers with Combinations of Parp Inhibitor and AcylfulvenesJan 29, 2024Pending
18/500,032Method for Treating Blood CancersNov 1, 2023Pending
18/238,512Illudin Analogs, Uses Thereof, and Methods for Synthesizing the SameAug 27, 2023Pending
18/349,256Treatment of Brain Metastases and CNS Metastases Using Illudins or Hydroxylureamethyl AcylfulveneJul 10, 2023Pending
18/319,919Cancer Drug Sensitivity Determining MarkersMay 18, 2023Pending
10 of 16 applications shown.
Pro members see all 16 published applications.
Pro members: see all 16 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited